CN104267122B - A kind of Azithromycin eye-drops related substance detection method - Google Patents

A kind of Azithromycin eye-drops related substance detection method Download PDF

Info

Publication number
CN104267122B
CN104267122B CN201410499659.6A CN201410499659A CN104267122B CN 104267122 B CN104267122 B CN 104267122B CN 201410499659 A CN201410499659 A CN 201410499659A CN 104267122 B CN104267122 B CN 104267122B
Authority
CN
China
Prior art keywords
drops
azithromycin
azithromycin eye
eye
exchange resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410499659.6A
Other languages
Chinese (zh)
Other versions
CN104267122A (en
Inventor
刘湘林
张明华
曹现峰
郑敬
李燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Guangdong HEC Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong HEC Pharmaceutical filed Critical Guangdong HEC Pharmaceutical
Priority to CN201410499659.6A priority Critical patent/CN104267122B/en
Publication of CN104267122A publication Critical patent/CN104267122A/en
Application granted granted Critical
Publication of CN104267122B publication Critical patent/CN104267122B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention provides a kind of related substance detection method of Azithromycin eye-drops, described method adopts cation exchange resin column to carry out pre-treatment to Azithromycin eye-drops test liquid, then the liquid to be measured after HPLC measures process, calculates the content of related substance by area normalization method or external standard method.Detection method provided by the invention effectively can get rid of ionic compound, particularly cationic compound, as benzalkonium chloride, to the interference that the related substance of Azithromycin eye-drops detects, effectively determine its related substances in Azithromycin eye-drops exactly.

Description

A kind of Azithromycin eye-drops related substance detection method
Technical field
The present invention relates to field of medicine and chemical technology, relate to a kind of detection method of related substance of Azithromycin eye-drops more specifically.
Background technology
Azithromycin is fifteen-membered ring macrolide antibiotics, has a broad antifungal spectrum, and except having antibacterial action to most of bacterium, chlamydia, mycoplasma also have good activity.Mechanism of action is identical with erythromycin, is mainly combined with the 50S subunit of bacterial ribosome, suppresses the albumen synthesis depending on RNA.Clinical acpuei pharyngitis, the acute tonsillitis being widely used in micrococcus scarlatinae and causing; The nasosinusitis that sensitive bacterial causes, tympanitis, acute bronchitis, AECB; Pneumonia caused by streptococcus pneumonia, haemophilus influenzae and mycoplasma pneumoniae; Chlamydia trachomatis and the urethritis caused by non-several drug resistance NEISSERIA GONORRHOEAE and cervicitis; The skin soft-tissue infection that sensitive bacterial causes.
At present, azithromycin can be made into various dosage form, and as tablet, dispersing tablet, injection, dry suspensoid agent, injection and eye drops etc., these formulations commercially all have sale.
Usually also have in Azithromycin eye-drops outside azithromycin, also can containing a series of auxiliary materials comprising antiseptic.Benzalkonium chloride is common antiseptic.As, containing the benzalkonium chloride of 0.003% in the AZASITE Azithromycin eye-drops that FDA2007 ratifies first.
Benzalkonium chloride as a kind of common medical antiseptic, its structural formula:
Wherein, n=8,10,12,14,16 or 18, the benzalkonium chloride composition that different manufacturers is produced is inconsistent, may be the benzalkonium chloride only having n=8, also may containing wherein several.Do not affect it containing multiple benzalkonium chloride to use in Azithromycin eye-drops as antiseptic.
Benzalkonium chloride is white waxy solid or yellow colloidal body, in the aobvious neutral or faintly alkaline reaction of aqueous solution, produces volume foam during jolting.Benzalkonium chloride very easily dissolves in water or ethanol, slightly soluble in ether, and belong to Cidex-7 class, it is dissociated into cationic reactive groups in aqueous, is a kind of cationic surfactant.
Benzalkonium chloride belongs to cationic antiseptic, and the solubleness in water is better, poor in the solubleness of organic phase.The retention of ionic compound in the reverse-phase chromatography being Stationary liquid with octadecylsilane Bonded Phase is all bad.In repeatedly analyte detection process, benzalkonium chloride retention time is unstable, and drift is very serious, and poor repeatability, therefore affects specificity and the accurate quantitative analysis of other impurity in Azithromycin eye-drops.In fact, all similar ionic compounds all can affect the accurate detection of other related substances of azithromycin because retention time is unstable.
In a kind of Azithromycin slow-release of prior art eye drops, the content assaying method (CN102590392B) of azithromycin discloses a kind of HPLC method getting rid of the potency of azithromycin of eye drops in polycarbophil interference Accurate Determining azithromycin.
The detection method (CN103245744A) of prior art azithromycin injection related substance, it comprises: get azithromycin B reference substance, and be solution with sodium chloride injection dilution, the test of abnormal toxicity tests method is carried out successively again by the order that these solution increase progressively according to injection rate IR, until when there is dead mouse result in the retrial of the test of a certain azithromycin B injection rate IR, injection rate IR used in the previous test of this test is decided to be the injection rate IR limit of azithromycin B; According to same method, measure the injection rate IR limit of azithromycin Gx and Erythromycin A iminoether; The content C of above-mentioned three kinds of materials and azithromycin in quantitative test medicine to be measured; According to each research on maximum utilized quantity and formulae discovery, obtain the l.o.i W1 of three kinds of related substances, W2 and W3; If≤W1, and≤W2, and≤W3, then the relevant thing content of medicine reaches security level, otherwise does not reach security level, and then reaches the object achieving quantitative evaluation.
Therefore in the prior art, all openly do not solve ionic compound (as preservative benzalkonium chloride) and affect the method that Azithromycin eye-drops related substance accurately detects.
The invention provides the method that one can get rid of ionic compound (as preservative benzalkonium chloride) interference that related substance detects in Azithromycin eye-drops, and then reach the related substance of Accurate Determining Azithromycin eye-drops.
Summary of the invention
Summary of the invention
The present inventor by test of many times, finally obtains one and effectively gets rid of the method that ionic compound (as preservative benzalkonium chloride) disturbs Azithromycin eye-drops related substance to detect.The method make use of ion exchange resin to eliminate ionic compound (as preservative benzalkonium chloride) in Azithromycin eye-drops sample solution, overcome when to detect difference/same batch Azithromycin eye-drops related substance under different time identical chromatographic conditions, because of ionic compound (as preservative benzalkonium chloride), to go out peak position drift indefinite and cause the problem of interference, ensure that each impurity accuracy detects simultaneously, as peak area, be not affected.Whether the application of usual sample-pretreating method in concrete analytical approach be suitable, is not that those skilled in the art can predict, needs tried inspection just can determine.
The invention provides a kind of Azithromycin eye-drops related substance detection method, described method specificity is good, favorable reproducibility.
Term definition
The present invention " v/v " refers to volume ratio.
Detailed Description Of The Invention
Azithromycin eye-drops related substance detection method provided by the invention, is characterized in that:
A) get Azithromycin eye-drops sample solution, remove ionic compound by ion exchange resin column, then obtain Azithromycin eye-drops liquid to be measured by the organic membrane filtration being connected to ion-exchange column outlet;
B) liquid to be measured configured is injected HPLC to detect, measure the content of Azithromycin eye-drops related substance;
C) measure the percentage composition of each impurity by area normalization method or calculate the content of each impurity by external standard method.
The ionic compound of removing of the present invention can be by anion-exchange resin column removing anionic compound or remove cationic compound by cation exchange resin column.
The method of described cation exchange resin column removing ionic compound first gets Azithromycin eye-drops sample solution quickly through cation exchange resin column, rinse adsorption column; Get above-mentioned Azithromycin eye-drops sample solution again and slowly add cation exchange resin column, leave standstill, discard just filtrate, get subsequent filtrate as Azithromycin eye-drops liquid to be measured.Time of repose can be 10 ~ 20min.
In certain embodiments, referred to by using cation exchange resin column removing preservative benzalkonium chloride by cation exchange resin column removing ionic compound.
In certain embodiments, the cation exchange resin column used, preparation method: get 001 × 7 type Zeo-karb and be about 500g, with 95% (volume ratio) alcohol immersion 24h, washes with water to without alcohol taste; The hydrochloric acid solution adding 1mol/L again soaks 4h, washes with water to neutrality; Soak 4h with 1mol/L sodium hydrate aqueous solution again, wash with water to neutrality; Finally soak with dilution and preserve, wherein said dilution is the mixed solution of the 1.73g/L ammonium dihydrogen phosphate aqueous solution-acetonitrile-methanol regulating about pH10.0 with ammoniacal liquor, and volume ratio is 7:6:7; Before use, get Zeo-karb, with Buchner funnel suction filtration to not dripping, load in the syringe of a small amount of absorbent cotton of bottom pad.
In certain embodiments, Azithromycin eye-drops related substance detection method provided by the invention, wherein the chromatographic condition of HPLC can be:
Instrument: high performance liquid chromatograph;
Chromatographic column: watersXbridgeC18,4.6 × 250mm, 5um;
Detecting device: UV-detector, determined wavelength 210nm;
Flow velocity: 1.0mL/min;
Column temperature: 60 DEG C;
Sample size: 100 μ L;
Gradient elution mode
Mobile phase A: take in ADSP 1.8g to 1L water, adds phosphoric acid,diluted or diluted sodium hydroxide solution adjusts pH to 8.9;
Mobile phase B: acetonitrile: methyl alcohol=3:1, volume ratio;
Working time: 93min.
Azithromycin eye-drops related substance detection method provided by the present invention, effectively can get rid of ionic compound in Azithromycin eye-drops to the interference of other related substance Accurate Determinings, particularly get rid of preservative benzalkonium chloride to the interference of other related substance Accurate Determinings, be suitable for the content measuring Azithromycin eye-drops related substance.
Accompanying drawing explanation
Fig. 1 shows the detection chromatogram of sample 1 in embodiment 1
Fig. 2 shows the detection chromatogram of sample 2 in embodiment 1
Fig. 3 shows the detection chromatogram of sample 3 in embodiment 1
Fig. 4 shows the detection chromatogram of sample 4 in embodiment 1
Fig. 5 shows the detection chromatogram of sample 5 in embodiment 2
Fig. 6 shows the detection chromatogram of sample 6 in embodiment 2
Embodiment
In order to make those skilled in the art understand technical scheme of the present invention better, below disclose further some non-limiting embodiments the present invention is described in further detail.
Reagent used in the present invention all can be buied from the market or can be obtained by method described in the invention preparation.
The preservative benzalkonium chloride that in embodiment 1, Azithromycin eye-drops is used only has n=12 benzalkonium chloride.
The preservative benzalkonium chloride that in embodiment 2, Azithromycin eye-drops is used includes n=12 and n=14 two kinds of benzalkonium chlorides.
Embodiment 1
Get Azithromycin eye-drops (AZASITE) about 10.0g, accurately weighed, put in 50mL measuring bottle, add dilution and be about 30mL, jolting 20min, then be settled to scale with dilution, shake up.Get supernatant 5mL, organic filter membrane (nylon, 0.45 μm, Φ 13mm, Tianjin is risen) filter, get subsequent filtrate, obtain the Azithromycin eye-drops liquid to be measured without Zeo-karb process.
Chromatographic condition:
Instrument: high performance liquid chromatograph;
Chromatographic column: watersXbridgeC18,4.6 × 250mm, 5um;
Detecting device: UV-detector, determined wavelength 210nm;
Flow velocity: 1.0mL/min;
Column temperature: 60 DEG C;
Sample size: 100 μ L;
Gradient elution mode
Mobile phase A: take in ADSP 1.8g to 1L water, adds phosphoric acid,diluted or diluted sodium hydroxide solution adjusts pH to 8.9;
Mobile phase B: acetonitrile: methyl alcohol=3:1, volume ratio;
Working time: 93min.
At different time by above-mentioned sample preparation method sample, be respectively sample 1,2,3,4, under identical chromatographic condition, under same detection environment, sample detection investigates the reservation situation of benzalkonium chloride.And pass through the position of sample introduction benzalkonium chloride reference substance determination benzalkonium chloride.
Detect 4 liquid to be measured of the Azithromycin eye-drops without Zeo-karb process respectively, detect collection of illustrative plates and see Fig. 1, Fig. 2, Fig. 3 and Fig. 4.
Testing result is as table 1
Show that benzalkonium chloride is detecting the instability of the retention time in sample, can constantly drift about through table results table 1 and profiling results Fig. 1, Fig. 2, Fig. 3 and Fig. 4.
Embodiment 2
Azithromycin eye-drops without Zeo-karb process liquid to be measured, hereinafter referred to as sample 5, prepares by embodiment 1 method.
Get Azithromycin eye-drops (AZASITE) about 10.0g, accurately weighed, put in 50mL measuring bottle, add dilution and be about 30mL, jolting 20min, then be settled to scale with dilution, shake up.Get supernatant 5mL, quickly through cation exchange resin column (rinse adsorption column), be connected with machine filter film (nylon, 0.45 μm, Φ 13mm, Tianjin is risen), then get supernatant 3mL, slowly add cation exchange resin column, filter after leaving standstill 15min, discard just filtrate 2mL, get subsequent filtrate and namely obtain Azithromycin eye-drops liquid to be measured after Zeo-karb process, hereinafter referred to as sample 6.
Chromatographic condition:
Instrument: high performance liquid chromatograph;
Chromatographic column: watersXbridgeC18,4.6 × 250mm, 5um;
Detecting device: UV-detector, determined wavelength 210nm;
Flow velocity: 1.0mL/min;
Column temperature: 60 DEG C;
Sample size: 100 μ L;
Gradient elution mode
Mobile phase A: take in ADSP 1.8g to 1L water, adds phosphoric acid,diluted or diluted sodium hydroxide solution adjusts pH to 8.9;
Mobile phase B: acetonitrile: methyl alcohol=3:1, volume ratio;
Working time: 93min.
Sample detection sample 5 and sample 6 under identical chromatographic condition, record chromatogram, investigates after cation exchange resin column process, the removal situation of benzalkonium chloride and the detection case of each impurity in sample.Testing result is as table 2, and chromatogram is as Fig. 5 and Fig. 6.
Visible, effectively get rid of the interference of benzalkonium chloride after treatment, little to each defects inspecting Influence on test result.
Table 2
To sum up embodiment 1 and embodiment 2 known, embodiment 1 shows that the related substance of the Azithromycin eye-drops containing benzalkonium chloride detects, and benzalkonium chloride will have a strong impact on the detection of the related substance of Azithromycin eye-drops due to peak transience.Embodiment 2 shows that the liquid to be measured of the Azithromycin eye-drops after cation exchange resin column detects, and effectively can get rid of the interference of benzalkonium chloride; Azithromycin eye-drops liquid to be measured testing result before and after the process of contrast cation exchange resin column is known, and the fluctuation of each impurity of the liquid to be measured after cation exchange resin column process is little, and maximum percentage composition deviation is 0.05%, and error is less.
Therefore a kind of Azithromycin eye-drops related substance detection method provided by the invention, effectively can get rid of the interference of benzalkonium chloride or other ionic compounds, the related substance of Accurate Determining Azithromycin eye-drops.
Method of the present invention is described by preferred embodiment, and related personnel obviously can change methods and applications as herein described or suitably change and combination in content of the present invention, spirit and scope, realizes and applies the technology of the present invention.Those skilled in the art can use for reference present disclosure, and suitable improving technique parameter realizes.Special needs to be pointed out is, all similar replacements and change apparent to those skilled in the art, they are all deemed to be included in the present invention.

Claims (2)

1. an Azithromycin eye-drops related substance detection method, is characterized in that:
A) get Azithromycin eye-drops sample solution, remove benzalkonium chloride by cation exchange resin column, then obtain Azithromycin eye-drops liquid to be measured by the organic membrane filtration being connected to ion-exchange column outlet;
B) liquid to be measured configured is injected HPLC to detect, measure the content of Azithromycin eye-drops related substance;
C) measure the percentage composition of each impurity by area normalization method or calculate the content of each impurity by external standard method;
By cation exchange resin column removing benzalkonium chloride method be wherein:
A) Azithromycin eye-drops sample solution is first got by cation exchange resin column, rinse adsorption column;
B) get above-mentioned Azithromycin eye-drops sample solution again and add cation exchange resin column, leave standstill 10 ~ 20min;
C) discard just filtrate, get subsequent filtrate as Azithromycin eye-drops liquid to be measured;
The preparation method of wherein said cation exchange resin column is:
A) get 001 × 7 type Zeo-karb and be about 500g, use 95% ethanol, volume ratio, soak 24h, wash with water to without alcohol taste;
B) hydrochloric acid solution adding 1mol/L again soaks 4h, washes with water to neutrality;
C) soak 4h with 1mol/L sodium hydrate aqueous solution again, wash with water to neutrality;
D) finally soak preservation with dilution, wherein said dilution is the mixed solution of the 1.73g/L ammonium dihydrogen phosphate aqueous solution-acetonitrile-methanol regulating about pH10.0 with ammoniacal liquor, and volume ratio is 7:6:7;
E) before use, get Zeo-karb, with Buchner funnel suction filtration to not dripping, load in the syringe of a small amount of absorbent cotton of bottom pad.
2. method according to claim 1, the chromatographic condition that wherein HPLC detects is:
Instrument: high performance liquid chromatograph;
Chromatographic column: watersXbridgeC18,4.6 × 250mm, 5um;
Detecting device: UV-detector, determined wavelength 210nm;
Flow velocity: 1.0mL/min;
Column temperature: 60 DEG C;
Sample size: 100 μ L;
Gradient elution mode
Mobile phase A: take in ADSP 1.8g to 1L water, adds phosphoric acid,diluted or diluted sodium hydroxide solution adjusts pH to 8.9;
Mobile phase B: acetonitrile: methyl alcohol=3:1, volume ratio;
Working time: 93min.
CN201410499659.6A 2014-09-25 2014-09-25 A kind of Azithromycin eye-drops related substance detection method Active CN104267122B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410499659.6A CN104267122B (en) 2014-09-25 2014-09-25 A kind of Azithromycin eye-drops related substance detection method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410499659.6A CN104267122B (en) 2014-09-25 2014-09-25 A kind of Azithromycin eye-drops related substance detection method

Publications (2)

Publication Number Publication Date
CN104267122A CN104267122A (en) 2015-01-07
CN104267122B true CN104267122B (en) 2016-01-06

Family

ID=52158663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410499659.6A Active CN104267122B (en) 2014-09-25 2014-09-25 A kind of Azithromycin eye-drops related substance detection method

Country Status (1)

Country Link
CN (1) CN104267122B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109633034B (en) * 2019-01-29 2021-05-14 宜昌东阳光生化制药有限公司 Method for detecting azithromycin genotoxic impurity
CN109870528B (en) * 2019-02-21 2022-07-15 北京悦康科创医药科技股份有限公司 Method for determining azithromycin capsule related substances by high performance liquid chromatography
CN111024844A (en) * 2019-12-18 2020-04-17 湖北省宏源药业科技股份有限公司 Method for detecting related impurities of azithromycin capsules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Rapid Determination of Benzalkonium Chloride in a Cosmetic;Huang Xiongfeng et al.;《Application Update 190》;20121231;全文 *
刘艳琴 等.高效液相色谱法同时测定化妆品中的3种苯扎氯铵同系物.《色谱》.2011,第29卷(第5期),第459页右栏. *
张琳 等.HPLC法同时测定阿奇霉素滴眼液中阿奇霉素及苯扎氯铵的含量.《齐鲁药事》.2012,第31卷(第12期),全文. *
汪洁.吸入液中异丙托溴铵和苯扎氯铵的HPLC测定.《中国医药工业杂志》.1996,第27卷(第9期),全文. *

Also Published As

Publication number Publication date
CN104267122A (en) 2015-01-07

Similar Documents

Publication Publication Date Title
El-Kosasy et al. Comparative study of 2-hydroxy propyl beta cyclodextrin and calixarene as ionophores in potentiometric ion-selective electrodes for neostigmine bromide
CN104267122B (en) A kind of Azithromycin eye-drops related substance detection method
Zheng et al. Evaluating polymer monolith in-tube solid-phase microextraction coupled to liquid chromatography/quadrupole time-of-flight mass spectrometry for reliable quantification and confirmation of quinolone antibacterials in edible animal food
CN109932455A (en) Detect the liquid matter analysis method of catecholamine metabolism object content in 24H urine
CN111208249B (en) Method for determining content of active ingredients of anthelmintic by high performance liquid chromatography
CN111208215B (en) Method for detecting impurity 2-mercaptobenzothiazole in ceftriaxone sodium
El-Gindy et al. Optimization and validation of a stability-indicating RP-HPLC method for determination of azithromycin and its related compounds
CN103175930B (en) A kind of HPLC analytical method measuring sodium sulphite content
CN103076325B (en) Quality control method for blood sugar-lowering preparation
CN104359989A (en) Liquid chromatography detecting method for 2,4-methylimidazole and 2-acetyl-4-tetrahydroxyl-buthylimidazole in caramel pigment
CN103995062B (en) Method for testing exenatide and impurities thereof by using high performance liquid chromatography
Martinovic-Bevanda et al. Spectrophotometric sequential injection determination of D-penicillamine based on a complexation reaction with nickel ion
CN108760937B (en) Determination of residual ethylenediamine in caspofungin acetate and application thereof
CN103424478B (en) Pirlimycin residue analysis method
CN102662023A (en) Method for detecting antifungal drug for external application
CN112710773B (en) Method for simultaneously detecting fosfomycin and diol thereof by adopting ion chromatography
CN105021731A (en) Gluconic acid detection method
CN106226304A (en) A kind of method utilizing acid-base indicator method to measure oligochitosan deacetylation
CN104792888A (en) Compound terramycin injection content determination method
CN110082445A (en) Method that is a kind of while measuring chlorhexidine gluconate and parachloroanilinum content
CN110208397A (en) High performance liquid chromatography that is a kind of while measuring two kinds of drug contents in terramycin Flunixin injection
CN115856160B (en) Method for measuring content of related substances in compound tranexamic acid tablet
CN102735788B (en) Method for analyzing and measuring etidronic acid and salts of etidronic acid in sample
CN108802273A (en) A kind of L-(-)The detection method of dibenzoyl tartaric acid
CN108802211B (en) Liquid phase detection method for related substances in cefquinome sulfate breast injectant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.